Clinical trial
Secondary Prevention of Venous Thrombo Embolism (VTE).
NCT00329238 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00329238 |
|---|---|
| Title | Secondary Prevention of Venous Thrombo Embolism (VTE). |
| Official title | A Phase III, Randomised, Multicenter, Double-blind, Parallel-group, Active Controlled Study to Evaluate the Efficacy and Safety of Oral Dabigatran Etexilate (150 mg Bid) Compared to Warfarin (INR 2.0-3.0) for the Secondary Prevention of Venous Thromboembolism. |
| Acronym | RE-MEDY |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Thromboembolism |
| Intervention type | Drug |
| Interventions | Dabigatran, Warfarin |
| Enrollment | 2,867 |
| Start date | May 1, 2006 |
| Primary completion | Oct 1, 2010 |
| First posted | May 24, 2006 |
| Last update posted | May 19, 2014 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Czechia, Denmark, Finland, France and 21 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: